Scientists develop method to quickly enhance immune-system proteins

November 5, 2018, Rice University
From left, Rice University bioengineer Han Xiao, graduate student Chenfei Yu and postdoctoral researcher Juan Tang monitor a sample in Xiao's lab. The researchers have developed pClick, a new technique to attach drugs or other substances to antibodies. Credit: Jeff Fitlow/Rice University

Rice University scientists have found a simple method to attach drugs or other substances to antibodies, the powerful proteins that are central to the body's immune system.

The Rice lab of bioengineer Han Xiao developed a technique called pClick, which uses a cross-linker that snaps to a specific site on and serves as a bridge to therapeutic molecules or nanomaterials without the need to re-engineer the antibody with harmful chemicals, enzymes or ultraviolet (UV) light.

All of those alternatives are used by companies and researchers to prepare antibodies for conjugation—the process of chemically modifying them.

"But our technology is straightforward, highly efficient and economical," said Xiao, who joined Rice last year with funding from the Cancer Prevention and Research Institute of Texas (CPRIT). "We use native antibodies with no engineering, no enzyme treatment, no chemical treatment, no UV treatment. People have tried to use all these things before to achieve site-specific conjugation. We don't need them."

The research is detailed in the American Chemical Society journal Bioconjugate Chemistry.

Antibodies are dimers, identical proteins that in this case come together in a "Y" shape, and the workhorses of the immune system. Their job is to recognize and bind to pathogens, facilitating the invaders' elimination. Antibodies either roam the blood stream or attach themselves to cells that need protection. Because they are ubiquitous in the body, modifying them is a way to treat disease.

That's not easy, Xiao said. "For the first generation of antibody conjugation, people used targets like lysine or cysteine residues to attach their therapeutic molecules," Xiao said. "But antibodies are so big, and there are so many lysine and , they can never control their positions. Each batch they make of a drug is different."

Rice University bioengineer Han Xiao and his team developed the simple pClick technique to attach drugs or other substances to antibodies, the powerful proteins that are central to the body's immune system. Credit: Jeff Fitlow/Rice University

He said second-generation research focused on site-specific conjugation to place therapeutic drugs at a particular location on the antibody. "That let them optimize the position of the drug, but to do so people needed to know the antibody's sequence and engineer it," Xiao said.

"Our next-generation work addresses two problems," he said. "First, we don't have to engineer antibodies. We use antibodies from the market for direct, site-specific conjugation. Second, we know exactly where our molecule goes on the antibody."

The key to proximity-induced conjugation is using non-canonical amino acids (ncAAs), synthetic hooks that can be made to covalently bind to a specific spot on a protein when it gets close enough (the "p" in pClick stands for proximity). Because antibodies are two-protein dimers, ncAAs bind one to a side and provide two spots for enhancement.

Xiao sees pClick as a general strategy for antibody conjugation by industry and academia. He noted tests to link a side chain protein to human and mouse antibodies conjugated with ncAA showed efficiencies of more than 90 percent. Stability tests showed the antibodies did not significantly degrade after two hours of incubation in human serum.

"The regions of the antibody protein we address are conserved across human and mouse, and we demonstrated that pClick works on both," he said. "This efficiency was a surprise, but it's important for the antibody-drug conjugate field."

Xiao's Rice lab plans to develop pClick for cancer immunotherapy. "We want to achieve different conjugations, from antibody-drug conjugates all the way to antibody-antibody conjugates, where we would mix two antibodies and they would click together," he said.

"We think we can have one antibody target the cancer cell, and the other antibody target the immune cell," Xiao added. "Then the antibodies will bring the cells together."

Explore further: New approach to cancer immunotherapy overcomes toxicity hurdle

More information: Chenfei Yu et al, Proximity-Induced Site-Specific Antibody Conjugation, Bioconjugate Chemistry (2018). DOI: 10.1021/acs.bioconjchem.8b00680

Related Stories

New approach to cancer immunotherapy overcomes toxicity hurdle

October 26, 2018
In an effort to develop more effective cancer treatments, scientists are looking for therapies that supercharge patients' immune systems. One possibility is to use antibodies that activate CD40, an immune-cell protein that, ...

Recent advances in site specific conjugations of antibody drug conjugates

July 13, 2016
Antibody-drug conjugates take the advantage of antigen specificity of monoclonal antibodies to deliver highly potent cytotoxic drugs selectively to antigen-expressing tumor cells.

Antibody identifier could speed development of therapies for cancer, other diseases

July 10, 2018
A research team led by a UCLA bioengineer has developed a model to predict the extent to which new laboratory-designed antibodies will be able to combat specific human diseases. This is the first time that a comprehensive ...

Engineering a safer antibody drug

May 2, 2018
An innovative approach to protein engineering could help make antibody-based drug therapies less toxic and more effective.

Scientists gain new insight on how antibodies interact with widespread respiratory virus

February 22, 2018
Scientists have found and characterized the activity of four antibodies produced by the human immune system that target an important protein found in respiratory syncytial virus (RSV), according to new research published ...

Recommended for you

New inflammation inhibitor discovered

November 16, 2018
A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action. By inhibiting a certain protein, the researchers were able ...

Pets can double as asthma antidote

November 16, 2018
(HealthDay)—The "hygiene hypothesis" holds that early exposure to a variety of microorganisms may decrease the risk for chronic inflammatory diseases, like asthma.

Infants born to obese mothers risk developing liver disease, obesity

November 16, 2018
Infant gut microbes altered by their mother's obesity can cause inflammation and other major changes within the baby, increasing the risk of obesity and non-alcoholic fatty liver disease later in life, according to researchers ...

New study shows NKT cell subsets play a large role in the advancement of NAFLD

November 16, 2018
Since 2015 it has been known that the gut microbiota could have a direct impact on nonalcoholic fatty liver disease (NAFLD), which affects up to 12% of adults and is a leading cause of chronic liver disease. In the November ...

Defense against intestinal infection in organism is affected by prostaglandin E2

November 15, 2018
The treatment of intestinal infections caused by some strains of the bacterium Escherichia coli, present in unsanitized or contaminated foods, may have a new ally.

No link between 'hypoallergenic' dogs and lower risk of childhood asthma

November 15, 2018
Growing up with dogs is linked to a lower risk of asthma, especially if the dogs are female, a new study from Karolinska Institutet and Uppsala University in Sweden shows. However, the researchers found no relation between ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.